Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique
- 11 January 2006
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (9) , 1888-1899
Abstract
Recent emerging biochemical data indicate that several important neuroregulatory genes and proteins may be involved in the etiology of schizophrenia and bipolar disorder. Additionally, the same genes appear to be targets of several psychotropic medications that are used to treat these disorders. Recent DNA microarray studies show that genes involved in synaptic neurotransmission, signal transduction, and glutamate/GABA regulation may be differentially regulated in brains of subjects with schizophrenia. We hypothesized that chronic administration of olanzapine to rats would alter expression of various genes that may be involved in the etiology of schizophrenia and mood disorders. Rats were administered olanzapine (N=20, 2 mg/kg/day) or sterile saline intraperitoneally (N=20) daily for 21 days. Control and olanzapine-treated frontal cortices were analyzed using cDNA microarray technology. The results showed significant downregulation of 31 genes and upregulation of 38 genes by greater than two-fold in the drug-treated brains vs controls. Our results provide evidence for altered regulation of genes involved with signal transduction and cell communication, metabolism and energy pathways, transport, immune response, nucleic acid metabolism, and neuronal growth factors. Real-time quantitative RT-PCR analysis verified the direction and magnitude of change in six genes of interest: calbindin 3, homer 1, regulator of G-protein signaling (RGS) 2, pyruvate kinase, Reelin and insulin 2. Western blotting showed significant upregulation in protein products for Reelin 410 and Reelin 180 kDa and downregulation for NMDA3B and RGS2. Our results show for the first time that olanzapine causes changes in levels of several important genes that may be involved in the etiology and treatment of schizophrenia and other psychiatric disorders.Keywords
This publication has 59 references indexed in Scilit:
- Modulation of Synaptic Plasticity and Memory by Reelin Involves Differential Splicing of the Lipoprotein Receptor Apoer2Neuron, 2005
- Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: A potential animal model for schizophrenia and autismSynapse, 2005
- Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brainEuropean Neuropsychopharmacology, 2005
- Assessing the validity of blood‐based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary reportAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005
- Reelin glycoprotein: structure, biology and roles in health and diseaseMolecular Psychiatry, 2004
- Microarray Analysis of Differentially Expressed Genes in Rat Frontal Cortex Under Chronic Risperidone TreatmentNeuropsychopharmacology, 2004
- Dysregulation of the fibroblast growth factor system in major depressionProceedings of the National Academy of Sciences, 2004
- Differential display polymerase chain reaction reveals increased expression of striatal rat glia-derived nexin following chronic clozapine treatmentThe Pharmacogenomics Journal, 2004
- A Genome-Wide Scan for Linkage to Chromosomal Regions in 382 Sibling Pairs With Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1Growth Hormone & IGF Research, 2000